Shopping Cart
Remove All
Your shopping cart is currently empty
Orticumab
(Synonyms: MLDL1278A) Copy Product Info
🥰Excellent
Synonyms: MLDL1278A
Catalog No. T77123 Copy Product Info
🥰Excellent
Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also shows significant promise for the treatment of autoimmune inflammatory conditions such as psoriasis.
Orticumab
Cas No. 1314241-10-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $413 | - | In Stock | |
| 5 mg | $1,230 | - | In Stock | |
| 10 mg | $1,990 | - | In Stock | |
| 25 mg | $2,950 | - | In Stock | |
| 50 mg | $3,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:≥95% (SDS-PAGE); 98.56% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also shows significant promise for the treatment of autoimmune inflammatory conditions such as psoriasis. |
| In vivo | Methods: Orticumab (10 mg/kg, intraperitoneal injection, once a week for three weeks) was used to treat B6.lpr.ApoE-/- mice (18 weeks old) fed a high-fat diet (HFD) and its therapeutic effect was observed. Results: Orticumab treatment reduced aortic arch atherosclerosis by 42.8% and CD68 macrophage subvalvular plaque staining by 30.5%. [1] |
| Synonyms | MLDL1278A |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | oxLDL |
| Molecular Weight | ~150 kDa |
| Cas No. | 1314241-10-5 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Orticumab in vivo | Orticumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.